经颅超声在帕金森病诊断与治疗的应用
Application of Transcranial Ultrasound in the Diagnosis and Treatment of Parkinson’s Disease
摘要: 帕金森病是常见的神经退行性疾病，早期症状不典型，而临床诊断又主要依靠症状与体征，不仅诊断困难，因帕金森病的临床异质性大，也难以与其他神经退行性病相鉴别。经颅超声检查提示中脑黑质高回声是诊断帕金森病的一个辅助诊断指标，这一回声特性对帕金森疾病患者的某些疾病特征具有提示作用，目前关于经颅聚焦超声应用于帕金森病治疗的研究也开始崭露头角。因此本文就经颅超声在帕金森病诊断及治疗中的研究进展进行综述。
Abstract: Parkinson’s disease is a widely recognized neurodegenerative disorder, yet its early symptoms often present atypically. The clinical diagnosis relies heavily on identifying these symptoms and signs, which makes accurate diagnosis challenging. Moreover, the significant clinical variability of Parkinson’s disease adds to the difficulty of distinguishing it from other neurodegenerative diseases. Transcranial ultrasound can reveal increased echogenicity in the substantia nigra of the midbrain, serving as a critical auxiliary diagnostic marker for Parkinson’s disease. This echogenicity provides valuable insights into specific characteristics of the disease in affected patients. Currently, research on the application of transcranial focused ultrasound in the treatment of Parkinson’s disease is beginning to emerge. Therefore, this paper reviews the research progress of transcranial ultrasound in the diagnosis and treatment of Parkinson’s disease.
文章引用：李沅蔚, 王志刚. 经颅超声在帕金森病诊断与治疗的应用[J]. 临床医学进展, 2025, 15(1): 1256-1263. https://doi.org/10.12677/acm.2025.151167

参考文献

[1] Wang, T., Shi, C., Luo, H., Zheng, H., Fan, L., Tang, M., et al. (2021) Neuroinflammation in Parkinson’s Disease: Triggers, Mechanisms, and Immunotherapies. The Neuroscientist, 28, 364-381. [Google Scholar] [CrossRef] [PubMed]
[2] Goel, A., Narayan, S.K. and Sugumaran, R. (2022) Neuropsychiatric Features, Health-Related Quality of Life, and Caregiver Burden in Parkinson’s Disease. Annals of Indian Academy of Neurology, 25, 1147-1152. [Google Scholar] [CrossRef] [PubMed]
[3] Chaudhuri, K.R., Azulay, J., Odin, P., Lindvall, S., Domingos, J., Alobaidi, A., et al. (2024) Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study. Drugs—Real World Outcomes, 11, 1-11. [Google Scholar] [CrossRef] [PubMed]
[4] Chu, Y., Hirst, W.D., Federoff, H.J., Harms, A.S., Stoessl, A.J. and Kordower, J.H. (2023) Nigrostriatal Tau Pathology in Parkinsonism and Parkinson’s Disease. Brain, 147, 444-457. [Google Scholar] [CrossRef] [PubMed]
[5] Prajjwal, P., Flores Sanga, H.S., Acharya, K., Tango, T., John, J., Rodriguez, R.S.C., et al. (2023) Parkinson’s Disease Updates: Addressing the Pathophysiology, Risk Factors, Genetics, Diagnosis, along with the Medical and Surgical Treatment. Annals of Medicine & Surgery, 85, 4887-4902. [Google Scholar] [CrossRef] [PubMed]
[6] Berg, D., Postuma, R.B., Bloem, B., Chan, P., Dubois, B., Gasser, T., et al. (2014) Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson’s Disease. Movement Disorders, 29, 454-462. [Google Scholar] [CrossRef] [PubMed]
[7] Fereshtehnejad, S., Yao, C., Pelletier, A., Montplaisir, J.Y., Gagnon, J. and Postuma, R.B. (2019) Evolution of Prodromal Parkinson’s Disease and Dementia with Lewy Bodies: A Prospective Study. Brain, 142, 2051-2067. [Google Scholar] [CrossRef] [PubMed]
[8] Virameteekul, S., Revesz, T., Jaunmuktane, Z., Warner, T.T. and de Pablo-Fernández, E. (2023) Clinical Diagnostic Accuracy of Parkinson’s Disease: Where Do We Stand? Movement Disorders, 38, 558-566. [Google Scholar] [CrossRef] [PubMed]
[9] Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N.L., Hernandez, L.F. and Obeso, J.A. (2017) Compensatory Mechanisms in Parkinson’s Disease: Circuits Adaptations and Role in Disease Modification. Experimental Neurology, 298, 148-161. [Google Scholar] [CrossRef] [PubMed]
[10] Obeso, J.A., Stamelou, M., Goetz, C.G., Poewe, W., Lang, A.E., Weintraub, D., et al. (2017) Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 32, 1264-1310. [Google Scholar] [CrossRef] [PubMed]
[11] Xie, L. and Hu, L. (2022) Research Progress in the Early Diagnosis of Parkinson’s Disease. Neurological Sciences, 43, 6225-6231. [Google Scholar] [CrossRef] [PubMed]
[12] Shin, H., Hong, S. and Youn, Y.C. (2022) Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism. Journal of Clinical Neurology, 18, 259-270. [Google Scholar] [CrossRef] [PubMed]
[13] Becker, G., Seufert, J., Bogdahn, U., Reichmann, H. and Reiners, K. (1995) Degeneration of Substantia Nigra in Chronic Parkinson’s Disease Visualized by Transcranial Color-Coded Real-Time Sonography. Neurology, 45, 182-184. [Google Scholar] [CrossRef] [PubMed]
[14] Berg, D., Roggendorf, W., Schröder, U., Klein, R., Tatschner, T., Benz, P., et al. (2002) Echogenicity of the Substantia Nigra. Archives of Neurology, 59, 999-1005. [Google Scholar] [CrossRef] [PubMed]
[15] Ahmadi, S., Bötzel, K., Levin, J., Maiostre, J., Klein, T., Wein, W., et al. (2020) Analyzing the Co-Localization of Substantia Nigra Hyper-Echogenicities and Iron Accumulation in Parkinson’s Disease: A Multi-Modal Atlas Study with Transcranial Ultrasound and MRI. NeuroImage: Clinical, 26, Article 102185. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, W., Yan, Z., Gao, J., Sun, L., Huang, X., Liu, Z., et al. (2013) Role and Mechanism of Microglial Activation in Iron-Induced Selective and Progressive Dopaminergic Neurodegeneration. Molecular Neurobiology, 49, 1153-1165. [Google Scholar] [CrossRef] [PubMed]
[17] Bartova, P., Skoloudik, D., Bar, M., Ressner, P., Hlustik, P., Herzig, R., et al. (2008) Transcranial Sonography in Movement Disorders. Biomedical Papers, 152, 251-258. [Google Scholar] [CrossRef] [PubMed]
[18] Walter, U., Dressler, D., Wolters, A., Wittstock, M. and Benecke, R. (2007) Transcranial Brain Sonography Findings in Clinical Subgroups of Idiopathic Parkinson’s Disease. Movement Disorders, 22, 48-54. [Google Scholar] [CrossRef] [PubMed]
[19] Huang, Y., Jeng, J., Tsai, C., Chen, L. and Wu, R. (2007) Movement Disorders, 22, 550-555. [Google Scholar] [CrossRef] [PubMed]
[20] Behnke, S., Double, K.L., Duma, S., Broe, G.A., Guenther, V., Becker, G., et al. (2007) Substantia Nigra Echomorphology in the Healthy Very Old: Correlation with Motor Slowing. NeuroImage, 34, 1054-1059. [Google Scholar] [CrossRef] [PubMed]
[21] Schweitzer, K.J., Behnke, S., Liepelt, I., Wolf, B., Grosser, C., Godau, J., et al. (2007) Cross-Sectional Study Discloses a Positive Family History for Parkinson’s Disease and Male Gender as Epidemiological Risk Factors for Substantia Nigra Hyperechogenicity. Journal of Neural Transmission, 114, 1167-1171. [Google Scholar] [CrossRef] [PubMed]
[22] Yilmaz, R., Behnke, S., Liepelt-Scarfone, I., Roeben, B., Pausch, C., Runkel, A., et al. (2016) Substantia Nigra Hyperechogenicity Is Related to Decline in Verbal Memory in Healthy Elderly Adults. European Journal of Neurology, 23, 973-978. [Google Scholar] [CrossRef] [PubMed]
[23] Berg, D. (2006) In Vivo Detection of Iron and Neuromelanin by Transcranial Sonography—A New Approach for Early Detection of Substantia Nigra Damage. Journal of Neural Transmission, 113, 775-780. [Google Scholar] [CrossRef] [PubMed]
[24] Berg, D., Behnke, S., Seppi, K., Godau, J., Lerche, S., Mahlknecht, P., et al. (2012) Enlarged Hyperechogenic Substantia Nigra as a Risk Marker for Parkinson’s Disease. Movement Disorders, 28, 216-219. [Google Scholar] [CrossRef] [PubMed]
[25] Zhang, S., Tao, K., Wang, J., Duan, Y., Wang, B. and Liu, X. (2020) Substantia Nigra Hyperechogenicity Reflects the Progression of Dopaminergic Neurodegeneration in 6-OHDA Rat Model of Parkinson’s Disease. Frontiers in Cellular Neuroscience, 14, Article 216. [Google Scholar] [CrossRef] [PubMed]
[26] Zhu, S., Wang, Y., Jiang, Y., Gu, R., Zhong, M., Jiang, X., et al. (2022) Clinical Features in Parkinson’s Disease Patients with Hyperechogenicity in Substantia Nigra: A Cross-Sectional Study. Neuropsychiatric Disease and Treatment, 18, 1593-1601. [Google Scholar] [CrossRef] [PubMed]
[27] Li, T., Shi, J., Qin, B., Fan, D., Liu, N., Ni, J., et al. (2019) Increased Substantia Nigra Echogenicity Correlated with Visual Hallucinations in Parkinson’s Disease: A Chinese Population-Based Study. Neurological Sciences, 41, 661-667. [Google Scholar] [CrossRef] [PubMed]
[28] del Toro Pérez, C., Amaya Pascasio, L., Arjona Padillo, A., Olivares Romero, J., Mejías Olmedo, M., Fernández Pérez, J., et al. (2021) Neurosonological Findings Related to Non-Motor Features of Parkinson’s Disease: A Systematic Review. Brain Sciences, 11, Article 776. [Google Scholar] [CrossRef] [PubMed]
[29] Yan, J., Li, K., Ge, Y., Li, W., Wang, P., Jin, H., et al. (2023) Quantitative Transcranial Sonography Evaluation of Substantia Nigra Hyperechogenicity Is Useful for Predicting Levodopa-Induced Dyskinesia in Parkinson Disease. Ultrasound in Medicine & Biology, 49, 607-615. [Google Scholar] [CrossRef] [PubMed]
[30] Toomsoo, T., Liepelt-Scarfone, I., Berg, D., Kerner, R., Pool, A., Kadastik-Eerme, L., et al. (2019) Effect of Age on Substantia Nigra Hyper-Echogenicity in Parkinson’s Disease Patients and Healthy Controls. Ultrasound in Medicine & Biology, 45, 122-128. [Google Scholar] [CrossRef] [PubMed]
[31] Fan, Y., Ma, J., Yang, D., Li, X., Liang, K., She, Z., et al. (2024) Clinical Findings of Hyperechoic Substantia Nigra in Patients with Parkinson’s Disease. European Journal of Neuroscience, 59, 2702-2714. [Google Scholar] [CrossRef] [PubMed]
[32] Sian-Hülsmann, J., Mandel, S., Youdim, M.B.H. and Riederer, P. (2011) The Relevance of Iron in the Pathogenesis of Parkinson’s Disease. Journal of Neurochemistry, 118, 939-957. [Google Scholar] [CrossRef] [PubMed]
[33] Li, K., Ge, Y., Gu, C., Zhang, J., Jin, H., Li, J., et al. (2020) Substantia Nigra Echogenicity Is Associated with Serum Ferritin, Gender and Iron-Related Genes in Parkinson’s Disease. Scientific Reports, 10, Article No. 8660. [Google Scholar] [CrossRef] [PubMed]
[34] Tao, A., Chen, G., Deng, Y. and Xu, R. (2019) Accuracy of Transcranial Sonography of the Substantia Nigra for Detection of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Ultrasound in Medicine & Biology, 45, 628-641. [Google Scholar] [CrossRef] [PubMed]
[35] Mei, Y., Yang, J., Wu, Z., Yang, Y. and Xu, Y. (2021) Transcranial Sonography of the Substantia Nigra for the Differential Diagnosis of Parkinson’s Disease and Other Movement Disorders: A Meta-Analysis. Parkinson’s Disease, 2021, 1-9. Https://doi.org/10.1155/2021/8891874
[36] Wang, L., Yu, T., Chai, B. and He, W. (2021) Transcranial Sonography in Differential Diagnosis of Parkinson Disease and Other Movement Disorders. Chinese Medical Journal, 134, 1726-1731. [Google Scholar] [CrossRef] [PubMed]
[37] Bowary, P. and Greenberg, B.D. (2018) Noninvasive Focused Ultrasound for Neuromodulation. Psychiatric Clinics of North America, 41, 505-514. [Google Scholar] [CrossRef] [PubMed]
[38] Hutchinson, E., Dahleh, M. and Hynynen, K. (1998) The Feasibility of MRI Feedback Control for Intracavitary Phased Array Hyperthermia Treatments. International Journal of Hyperthermia, 14, 39-56. [Google Scholar] [CrossRef] [PubMed]
[39] Baek, H., Lockwood, D., Mason, E.J., Obusez, E., Poturalski, M., Rammo, R., et al. (2022) Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders. Frontiers in Neurology, 13, Article 880814. [Google Scholar] [CrossRef] [PubMed]
[40] Martínez-Fernández, R., Rodríguez-Rojas, R., del Álamo, M., Hernández-Fernández, F., Pineda-Pardo, J.A., Dileone, M., et al. (2018) Focused Ultrasound Subthalamotomy in Patients with Asymmetric Parkinson’s Disease: A Pilot Study. The Lancet Neurology, 17, 54-63. [Google Scholar] [CrossRef] [PubMed]
[41] Grogan, D.P., Abduhalikov, T., Kassell, N.F. and Moosa, S. (2024) Future Directions of MR-Guided Focused Ultrasound. Magnetic Resonance Imaging Clinics of North America, 32, 705-715. [Google Scholar] [CrossRef] [PubMed]
[42] Zhong, Y., Liao, J., Liu, X., Tian, H., Deng, L. and Long, L. (2023) Low Intensity Focused Ultrasound: A New Prospect for the Treatment of Parkinson’s Disease. Annals of Medicine, 55, Article 2251145. [Google Scholar] [CrossRef] [PubMed]
[43] Gasca-Salas, C., Fernández-Rodríguez, B., Pineda-Pardo, J.A., Rodríguez-Rojas, R., Obeso, I., Hernández-Fernández, F., et al. (2021) Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson’s Disease Dementia. Nature Communications, 12, Article No. 779. [Google Scholar] [CrossRef] [PubMed]

为你推荐